Cardiovascular Risk and Chronic Obstructive Pulmonary Disease

Официальное название

Cardiovascular Risk and Chronic Obstructive Pulmonary Disease (COPD)

Обзор

The principal objective of the study is to measure parameters of inflammation, oxidative stress, and vascular, respiratory, and peripheral muscle function parameters, and identify parameters indicative of evolving cardiovascular risk (CVR) in COPD patients, using multivariate analysis.

Подробное описание

Reduced lung function is a major risk factor for cardiovascular mortality (CV), regardless of age, sex and history of smoking. Similarly, CV events are known causes of mortality in patients with chronic obstructive pulmonary disease (COPD). The investigators propose to determine the parameters influencing the evolution of CV risk in a cohort of COPD patients followed over 5 years. For this the investigators will study the role of inflammation, oxidative stress, and vascular, respiratory and peripheral muscle function parameters.

In order to study a sufficient number of patients the investigators propose to group data from two cohorts: a first cohort of 121 COPD patients that already exists (currently closed to inclusions but still undergoing follow-up (NCT00404430)) and a new cohort of 150, decompensated or not, COPD patients.

This study is of major scientific interest and will enable to obtain extremely important information to better understand COPD.

Первичные конечные точки

• Change of the pulse wave velocity (PWV) [Срок оценки: During 5 years since inclusion (once a year)]

Вторичные конечные точки (5)

• Monitoring of COPD exacerbations compared to evolution of PWV [Срок оценки: During 5 years since inclusion]
• Relationship between the new cardiovascular (CV) events and the evolution of the PWV. [Срок оценки: During 5 years since inclusion (once a year)]
• Correlations between the parameters of severity of pulmonary disease and physical activity. [Срок оценки: During 5 years since inclusion (once a year)]
• Prevalence of nocturnal "non-dipping" of blood pressure during COPD. [Срок оценки: During 5 years since inclusion (once a year)]
• Impact of sleep disorders and sleep apnea syndrome on the evolution of CVR during COPD. [Срок оценки: At inclusion visit]

Критерии участия

Критерии включения

For patients with stable COPD:

• Men or women aged 18 to 85
• FEV1/FVC < 70% or proven BPCO
• Patients who have given their free and informed consent in writing

For patients with decompensated COPD:

• Men or women aged 18 to 85
• FEV1/FVC < 70% or proven BPCO
• At the time of acute respiratory failure (ARF), when admitted to hospital:

• Respiratory rate > 25 cycles per minute
• PaCO2 > 45 mmHg
• blood pH < 7.35
• When included in the study:

• pH > 7.33 at the end of ARF, 2 days in a row, or 3 to 7 days post-D1 decompensation (admission to the hospital)
• Fever < 38.5°C
• Patients who have given their free and informed consent in writing

Критерии исключения

• Obvious evolving infection or CRP > 100 mg/L
• Cardiac decompensation considered the main cause of decompensation or chronic heart failure with LVEF < 45%
• Evolving neoplasia
• On antioxidants: N-acetyl-cysteine, selenium, vit. C, vit. E
• Pregnant or nursing women
• Patients under tutorship or curatorship
• Patients participating in a drug clinical research study
• Patients not affiliated to the French social security system (or equivalent)
• Patients deprived of liberty or hospitalized without consent.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения

Когортное

Центры проведения

Франция · 1 центр

• University Grenoble Hospital — Grenoble

Публикации

• Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004 Jul;59(7):574-80. doi: 10.1136/thx.2003.019588. PMID 15223864
• Mallia P, Johnston SL. Mechanisms and experimental models of chronic obstructive pulmonary disease exacerbations. Proc Am Thorac Soc. 2005;2(4):361-6; discussion 371-2. doi: 10.1513/pats.200504-025SR. PMID 16267363
• de Torres JP, Cordoba-Lanus E, Lopez-Aguilar C, Muros de Fuentes M, Montejo de Garcini A, Aguirre-Jaime A, Celli BR, Casanova C. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006 May;27(5):902-7. doi: 10.1183/09031936.06.00109605. Epub 2006 Feb 2. PMID 16455829
• Malo O, Sauleda J, Busquets X, Miralles C, Agusti AG, Noguera A. [Systemic inflammation during exacerbations of chronic obstructive pulmonary disease]. Arch Bronconeumol. 2002 Apr;38(4):172-6. Spanish. PMID 11953269
• Dekhuijzen PN, Aben KK, Dekker I, Aarts LP, Wielders PL, van Herwaarden CL, Bast A. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996 Sep;154(3 Pt 1):813-6. doi: 10.1164/ajrccm.154.3.8810624. PMID 8810624
• Rahman I. The role of oxidative stress in the pathogenesis of COPD: implications for therapy. Treat Respir Med. 2005;4(3):175-200. doi: 10.2165/00151829-200504030-00003. PMID 15987234
• Heunks LM, Vina J, van Herwaarden CL, Folgering HT, Gimeno A, Dekhuijzen PN. Xanthine oxidase is involved in exercise-induced oxidative stress in chronic obstructive pulmonary disease. Am J Physiol. 1999 Dec;277(6):R1697-704. doi: 10.1152/ajpregu.1999.277.6.R1697. PMID 10600916
• Yende S, Waterer GW, Tolley EA, Newman AB, Bauer DC, Taaffe DR, Jensen R, Crapo R, Rubin S, Nevitt M, Simonsick EM, Satterfield S, Harris T, Kritchevsky SB. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax. 2006 Jan;61(1):10-6. doi: 10.1136/thx.2004.034181. Epub 2005 Nov 11. PMID 16284220

Идентификаторы

NCT: NCT03014609 · 38RC16.245

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗